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CORRESPONDENCE 
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Chordoid meningioma represents a rare meningioma variant. It is histologically defined by 
presence of trabeculae of eosinophilic and vacuolated epithelioid cells within a mucin-rich 
stroma [7]. The term chordoid meningioma was first used by Kepes et al. in 1988 [5], who 
published a series of seven cases. In a subsequent larger series of 42 cases, a considerable 
risk of recurrence even after total resection was identified [4]. Based on these findings, 
chordoid meningiomas are per definition graded as WHO grade II [7].  
For several variants of meningioma, associations with distinct genetic events have been 
identified. Examples are KLF4/TRAF7 mutations in secretory meningioma, enrichment for 
AKT1 mutations in meningothelial meningioma, SMARCE1 mutations in clear cell 
meningioma, and BAP1 mutation or deletion in rhabdoid meningioma [2,3,9,12] [11]. So far, 
no distinct mutation has been identified for chordoid meningioma. Also, no unique DNA 
methylation pattern has been found for chordoid meningioma [8,10]. For angiomatous, 
metaplastic, and microcystic meningioma, an association with gain of chromosome 5 has 
been reported [1,6]. Therefore, we sought to identify potential characteristic chromosomal 
alterations associated with chordoid histology. We compiled a cohort of 40 patients with 
chordoid meningiomas. Clinical follow-up data were available of 30 patients, DNA 
methylation data of 38 patients (Suppl. Table 1), both clinical follow-up and DNA methylation 
data were obtained for 28 patients. Tissue and clinical data were used in accordance with 
local ethical approval. Methods are described in the supplementary material. Meningiomas 
with chordoid differentiation were most common in frontal falx localization (Suppl. Table 1). 
All cases were reviewed according to the WHO classification 2016. None of these chordoid 
meningiomas had criteria for WHO grade II other than chordoid histology. All but one had 
chordoid differentiation in >50% of the respective tumor specimens, one single case 
presented with chordoid morphology in only 40% of the embedded material.  
Chordoid meningiomas showed significant enrichment for deletions of chromosomal arm 2p 
(p<0.0001): While 17/38 (45%) chordoid meningioma had 2p deletion, only 66/526 (12.5%) 
meningiomas of other subtypes carried this aberration (p<0.0001, Fig 1a-b, Suppl. Table 1, 
2). The enrichment for deletion of 2p was still evident when restricting the control group to 
WHO grade II (Fig 1c).  
We next sought to test the value of chordoid morphology for prediction of outcome in the 30 
patients with available clinical follow-up data in comparison to a cohort of 192 meningioma 
patients with tumors of other subtypes (Suppl. Table 1). Time to tumor recurrence in patients 
with chordoid meningiomas was significantly worse than in patients with WHO grade I 
meningiomas (p=0.01). In turn, outcome was statistically not different from patients with non-
chordoid meningiomas of WHO grade II (p=0.14), supporting the current standard of 
assigning chordoid meningioma to WHO grade II (Fig 1d). Of note, although significantly 
associated with chordoid differentiation, deletion of 2p was not an independent predictor of 
outcome, neither across all patients nor within patients with chordoid meningiomas (Suppl. 
Fig 1a, b, chordoid meningioma patients in this analysis restricted to the 28 patients with 
available molecular data and clinical follow-up). As mentioned before, chordoid meningiomas 
do not fall into a distinct DNA methylation group but dissolve into all clinically relevant 
subgroups. Of the 38 chordoid meningiomas with DNA methylation data in this cohort, 24 fell 
into benign Methylation Classes (MCs), 13 into intermediate MCs, one into the MC malignant 
of meningiomas. As chordoid meningioma are per definition WHO grade II but grouped with 
MCs of different malignancy, we tested in the 28 patients with follow-up data whether 
subgrouping of chordoid meningioma by DNA methylation further improves the accuracy of 
outcome prediction also for this particular histological subtype. Assignment to DNA 
methylation subgroups was indeed able to predict outcome with higher accuracy than the 
histological grading (Fig 1e). While the cohort of chordoid meningioma patients on average 
had an outcome according to patients with other types of WHO grade II meningiomas, DNA 
methylation-based classification allotted the chordoid meningiomas to subgroups that more 
precisely predicted clinical outcome (Suppl. Fig 1c, d). This higher predictive power of DNA 
methylation profiling indicates that subgroups of lower or higher risk of recurrence, 
respectively, can be identified by epigenetic analysis. 
Finally, we assessed whether certain mutations are enriched in chordoid meningioma. Panel 
sequencing data was already available for 11 samples from previous studies and could be 
supplemented by data from 10 additional tumors (Suppl. Figure 2). In line with a frequency of 
22q deletion below the average of the compound cohort of other meningioma subtypes (Fig 
1a-c), NF2 mutations were comparatively rare with only three (14.3%) mutant cases. AKT1 
or SMO hotspot and TERT promoter mutations were absent. Four chordoid meningiomas 
(19%) had isolated TRAF7 mutations in absence of KLF4 or AKT1 mutations, one of those 
had a 2p deletion. One chordoid meningioma carried a PIK3CA hotspot mutation.  
While deletion of 2p is significantly associated with chordoid morphology, it is by far not 
observed in all cases, and also not restricted to chordoid meningioma. In conjunct with the 
low frequency of otherwise known mutations in meningioma, this points towards additional, 
as of yet not discovered aberrations in this subtype. However, we were not able to compile a 
cohort of these rare cases with sufficient high-quality DNA or RNA and matched blood for 
more comprehensive whole-exome, whole-genome sequencing, or RNA sequencing. 
Upcoming large consortia dedicated to meningioma research may collect the critical amount 
of samples in order to pursue these efforts. This may also elucidate further clinical 
implications of 2p alterations, which cannot yet be inferred from the present data. For now, 
our data shows that DNA methylation profiling can improve the diagnostic accuracy of 
outcome prediction in chordoid meningioma. 
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Legend to Figure 
Integrated copy number plots for 38 chordoid meningiomas (a), 526 meningiomas across all 
WHO grades (b), and 166 WHO grade II meningiomas (c) show the enrichment for deletions 
of 2p in chordoid meningioma. The probability of recurrence-free survival for the chordoid 
meningioma patients investigated here was statistically not different from that of other WHO 
grade II meningioma patients (d). In line, separating chordoid meningiomas from other WHO 
grade II meningiomas does not add to the prediction power of the classification. The 
stratification for DNA methylation classes, however, strongly increases the predictive power 
in a Brier prediction plot (e).  
References 
 
1  Abedalthagafi MS, Merrill PH, Bi WL et al. (2014) Angiomatous meningiomas have a distinct 
genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. 
Oncotarget 5: 10596‐10606  
2  Brastianos PK, Horowitz PM, Santagata S et al. (2013) Genomic sequencing of meningiomas 
identifies oncogenic SMO and AKT1 mutations. Nat Genet 45: 285‐289  
3  Clark VE, Erson‐Omay EZ,  Serin A et al.  (2013) Genomic analysis of non‐NF2 meningiomas 
reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339: 1077‐1080  
4  Couce ME, Aker FV, Scheithauer BW (2000) Chordoid meningioma: a clinicopathologic study 
of 42 cases. The American journal of surgical pathology 24: 899‐905  
5  Kepes  JJ, Chen WY, Connors MH, Vogel  FS  (1988)  "Chordoid" meningeal  tumors  in  young 
individuals  with  peritumoral  lymphoplasmacellular  infiltrates  causing  systemic 
manifestations of the Castleman syndrome. A report of seven cases. Cancer 62: 391‐406  
6  Ketter R, Kim YJ, Storck S et al. (2007) Hyperdiploidy defines a distinct cytogenetic entity of 
meningiomas. Journal of neuro‐oncology 83: 213‐221  
7  Louis  DN,  Perry  A,  Reifenberger  G  et  al.  (2016)  The  2016  World  Health  Organization 
Classification of Tumors of the Central Nervous System: a summary. Acta neuropathologica 
131: 803‐820  
8  Olar A, Wani KM, Wilson CD et al.  (2017) Global epigenetic profiling  identifies methylation 
subgroups  associated with  recurrence‐free  survival  in meningioma. Acta  neuropathologica 
133: 431‐444  
9  Reuss DE, Piro RM, Jones DT et al. (2013) Secretory meningiomas are defined by combined 
KLF4 K409Q and TRAF7 mutations. Acta neuropathologica 125: 351‐358  
10  Sahm F, Schrimpf D, Stichel D et al. (2017) DNA methylation‐based classification and grading 
system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18: 682‐694  
11  Shankar GM, Abedalthagafi M, Vaubel RA et al. (2017) Germline and somatic BAP1 mutations 
in high‐grade rhabdoid meningiomas. Neuro Oncol 19: 535‐545  
12  Smith MJ, O'Sullivan J, Bhaskar SS et al. (2013) Loss‐of‐function mutations in SMARCE1 cause 
an inherited disorder of multiple spinal meningiomas. Nat Genet 45: 295‐298  
 
 
 
 

